| 王杰,杨雪晴,杨艺萱,等.特立帕肽治疗骨折延迟愈合和不愈合的系统综述.骨科,2026,17(1): 55-61. |
| 特立帕肽治疗骨折延迟愈合和不愈合的系统综述 |
| Systematic review of teriparatide treatment for delayed union and nonunion of fractures |
| 投稿时间：2025-07-10 |
| DOI：10.3969/j.issn.1674-8573.2026.01.011 |
| 中文关键词: 特立帕肽 甲状旁腺激素 骨折延迟愈合 骨折不愈合 |
| 英文关键词: Teriparatide Parathyroid hormone Fracture delayed union Fracture nonunion |
| 基金项目: |
|
| 摘要点击次数: 17 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 系统探讨特立帕肽治疗骨折延迟愈合和不愈合的临床疗效和安全性。方法 检索中国知网、万方、维普、中国生物医学文献数据库、PubMed、Web of Science、Embase、Cochrane Library数据库中特立帕肽治疗骨折延迟愈合/不愈合的相关文献，检索时间自建库以来至2025年2月1日。根据纳入标准提取文献基本特征、特立帕肽的使用、骨折愈合情况、不良反应等。结果 特立帕肽主要有20 μg和56.5 μg两种剂量，分别对应每日1次和每周1次的使用频率，给药途径均为皮下注射，连续给药时间最短8周，最长2年，涉及148例病人，其中143例达到临床治愈或好转，4例未愈合，1例失访。结论 特立帕肽对于骨折延迟愈合和不愈合的临床疗效和安全性较好，可以在临床中推广应用，但目前尚不能确定其最佳介入时机及治疗剂量和时长，临床医生使用时需结合病人实际情况制定个体化治疗方案，未来需要更多高质量的临床研究来验证其疗效和安全性。 |
| 英文摘要: |
| Objective To systematically investigate the clinical efficacy and safety of teriparatide in the treatment of delayed union and nonunion of fractures. Methods Literature on teriparatide for delayed union/nonunion fractures was retrieved from databases including CNKI, Wanfang, VIP, CBM, PubMed, Web of Science, Embase, and Cochrane Library, covering publications from inception to February 1, 2025. Based on the inclusion criteria, the basic characteristics of the literature, the use of teriparatide, fracture healing status, and adverse reactions were extracted. Results Teriparatide was administered at two primary doses: 20 μg daily and 56.5 μg weekly, both via subcutaneous injection. The treatment duration ranged from 8 weeks to 2 years, involving 148 patients. Among them, 143 patients achieved clinical cure or improvement, 4 patients did not heal, 1 patient was lost to follow-up. Conclusion Teriparatide demonstrates favorable clinical efficacy and safety for delayed union and nonunion fractures, supporting its clinical application. However, the optimal timing of intervention as well as the appropriate dosage and duration of treatment, remain undetermined. Clinicians should develop individualized treatment plans based on patient-specific factors. Future high-quality clinical trials are needed to validate its efficacy and safety. |
|
查看全文
下载PDF阅读器 |
| 关闭 |
|
|
|
